Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03514641 · ClinicalTrials.gov registry record · Phase 2
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
A Phase 2 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 2
- Development phase
- 673
- Enrollment target
NCT03514641: Completed Phase 2 study, sponsored by Theracos.
NCT03514641 is a Phase 2 study that has completed, run by Theracos. The registered enrollment target is 673 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (406% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03514641, a Phase 2 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 673 participants
- Enrollment target
Study Summary
This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies were to be obtained in a single consent form. Approximately 680 male or female adult subjects were to be enrolled.
Primary Outcome
Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared to placebo
Interventions
- DRUG Placebo
- DRUG Bexagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 673 participants |
| Start Date | 2017-10-18 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 2 |
What the finished NCT03514641 record still lists
NCT03514641 is an interventional study that assigns participants to a tested intervention. The registered 673 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (406% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03514641 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03514641 about?
NCT03514641 is a clinical study titled "An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension". This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies were to be obtained in a single consent form. Approximately 680 male or...
What is the current status of trial NCT03514641?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 673 participants. The study started on 2017-10-18. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03514641?
The interventions under investigation include: Placebo (DRUG), Bexagliflozin (DRUG).
Who is sponsoring clinical trial NCT03514641?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03514641's enrollment target sits among peer trials
673 48th of 2000 higher than 1,953 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06335381 · 674 participants · NA
MOMs Chat and Care Study
- NCT06757634 · 674 participants · Phase 3
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- NCT05452031 · 672 participants · NA
A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers
- NCT05493254 · 672 participants · NA
Enhancing Smoking Cessation Via Telehealth Options in Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI